Cargando…

Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer

Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor cells, regulatory T cells, and OX40 + and PD-1 + T lymphocytes counts) in periphera...

Descripción completa

Detalles Bibliográficos
Autores principales: Palazón-Carrión, Natalia, Jiménez-Cortegana, Carlos, Sánchez-León, M. Luisa, Henao-Carrasco, Fernando, Nogales-Fernández, Esteban, Chiesa, Massimo, Caballero, Rosalía, Rojo, Federico, Nieto-García, María-Adoración, Sánchez-Margalet, Víctor, de la Cruz-Merino, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277895/
https://www.ncbi.nlm.nih.gov/pubmed/34257359
http://dx.doi.org/10.1038/s41598-021-93838-w
_version_ 1783722149943443456
author Palazón-Carrión, Natalia
Jiménez-Cortegana, Carlos
Sánchez-León, M. Luisa
Henao-Carrasco, Fernando
Nogales-Fernández, Esteban
Chiesa, Massimo
Caballero, Rosalía
Rojo, Federico
Nieto-García, María-Adoración
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
author_facet Palazón-Carrión, Natalia
Jiménez-Cortegana, Carlos
Sánchez-León, M. Luisa
Henao-Carrasco, Fernando
Nogales-Fernández, Esteban
Chiesa, Massimo
Caballero, Rosalía
Rojo, Federico
Nieto-García, María-Adoración
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
author_sort Palazón-Carrión, Natalia
collection PubMed
description Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor cells, regulatory T cells, and OX40 + and PD-1 + T lymphocytes counts) in peripheral blood of patients diagnosed with advanced breast cancer were analyzed along of first line antineoplastic therapy. Subsequently, a comparison between groups with clinical benefit versus progression of disease and with a healthy women cohort was executed. Results reflected that patients showed higher basal levels of myeloid derived suppressor cells (35.43, IR = 180.73 vs 17.53, IR = 16.96 cells/μl; p = 0.001) and regulatory T cells (32.05, IR = 29.84 vs 22.61, IR = 13.57 cells/μl; p = 0.001) in comparison with healthy women. Furthermore, an increase in the number of activated T lymphocytes (expressing OX40), a decrease of immune inhibitory cells (MDSCs and Tregs) and inhibited T lymphocytes (expressing PD-1) were observed along the treatment in patients with clinical benefit (p ≤ 0.001). The opposite trend was observed in the case of disease progression. These findings suggest that some critical immune elements can be easily detected and measured in peripheral blood, which open a new opportunity for translational research, as they seem to be correlated with clinical evolution, at least in ABC.
format Online
Article
Text
id pubmed-8277895
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82778952021-07-15 Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer Palazón-Carrión, Natalia Jiménez-Cortegana, Carlos Sánchez-León, M. Luisa Henao-Carrasco, Fernando Nogales-Fernández, Esteban Chiesa, Massimo Caballero, Rosalía Rojo, Federico Nieto-García, María-Adoración Sánchez-Margalet, Víctor de la Cruz-Merino, Luis Sci Rep Article Identification of the different elements intervening at the tumor microenvironment seems key to explain clinical evolution in several tumor types. In this study, a set of immune biomarkers (myeloid derived suppressor cells, regulatory T cells, and OX40 + and PD-1 + T lymphocytes counts) in peripheral blood of patients diagnosed with advanced breast cancer were analyzed along of first line antineoplastic therapy. Subsequently, a comparison between groups with clinical benefit versus progression of disease and with a healthy women cohort was executed. Results reflected that patients showed higher basal levels of myeloid derived suppressor cells (35.43, IR = 180.73 vs 17.53, IR = 16.96 cells/μl; p = 0.001) and regulatory T cells (32.05, IR = 29.84 vs 22.61, IR = 13.57 cells/μl; p = 0.001) in comparison with healthy women. Furthermore, an increase in the number of activated T lymphocytes (expressing OX40), a decrease of immune inhibitory cells (MDSCs and Tregs) and inhibited T lymphocytes (expressing PD-1) were observed along the treatment in patients with clinical benefit (p ≤ 0.001). The opposite trend was observed in the case of disease progression. These findings suggest that some critical immune elements can be easily detected and measured in peripheral blood, which open a new opportunity for translational research, as they seem to be correlated with clinical evolution, at least in ABC. Nature Publishing Group UK 2021-07-13 /pmc/articles/PMC8277895/ /pubmed/34257359 http://dx.doi.org/10.1038/s41598-021-93838-w Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Palazón-Carrión, Natalia
Jiménez-Cortegana, Carlos
Sánchez-León, M. Luisa
Henao-Carrasco, Fernando
Nogales-Fernández, Esteban
Chiesa, Massimo
Caballero, Rosalía
Rojo, Federico
Nieto-García, María-Adoración
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
title Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
title_full Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
title_fullStr Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
title_full_unstemmed Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
title_short Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
title_sort circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277895/
https://www.ncbi.nlm.nih.gov/pubmed/34257359
http://dx.doi.org/10.1038/s41598-021-93838-w
work_keys_str_mv AT palazoncarrionnatalia circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT jimenezcorteganacarlos circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT sanchezleonmluisa circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT henaocarrascofernando circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT nogalesfernandezesteban circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT chiesamassimo circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT caballerorosalia circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT rojofederico circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT nietogarciamariaadoracion circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT sanchezmargaletvictor circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT delacruzmerinoluis circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer
AT circulatingimmunebiomarkersinperipheralbloodcorrelatewithclinicaloutcomesinadvancedbreastcancer